Laboratory findingsHaematologyThere

Laboratory findingsHaematologyThere were 44 (3.1%) reports of anaemia in the neratinib arm of study 3004 of which 4 (0.3%) were ≥ grade 3, compared to 16 (1.1%) reports in the placebo arm of which 1 (0.1%) were ≥ grade 3. The median % change from baseline to minimum post-baseline for haemoglobin was -5.93% for neratinib vs -3.10% for placebo. The incidence of leukopenia or neutropenia was 3.1% for neratinib vs 2.3% for placebo. The median % change from baseline to minimum post-baseline was also comparable for leucocyte subclasses between neratinib and placebo. The incidence of thrombocytopenia was 0.9% for neratinib vs 0.4% for placebo. The median % change from baseline to minimum post-baseline was also comparable for platelet count between neratinib and placebo.